Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

REBIOSTENT · Reinforced Bioresorbable Biomaterials for Therapeutic Drug Eluting Stents

FP7Status: CLOSED1 January 201431 December 2016EU funding €4,579,131

Active therapeutic biodegradable and biocompatible materials are highly in demand. These are required for the production of medicinal products in a variety of areas including implant technology, tissue engineering, drug delivery and wound healing. Within implant technology such biomaterials can be used for dental, bone and cardiovascular implants. Tailored mechanical properties, biocompatibility and degradation rate is the key to the development for a specific implant.Stents are tubular type implants that are deployed most commonly to recover the shape of narrowed arterial segments. Although, the clinical use of stents is widespread, they cause adverse responses including inflammation, in-stent restenosis and thrombosis. Endothelialisation of the stent greatly reduces these adverse reactions. In contrast to permanent stents there is great attraction in the notion of a biodegradable stent that recovers and maintains arterial shape and then gradually disappears and avoids further complications.In this multi-institution & disciplinary SME focussed project we will aim to provide the technological framework that leads to the production of reinforced polymeric biomaterials tailored towards stent manufacturing without adverse effects. Both natural and synthetic polymers will be produced and used. These will be reinforced and functionalised using a variety of techniques. Controlled delivery of suitable positive additives including antimitotic factors will be aimed for and their release monitored. These highly functionalised active biomaterials will be characterised thoroughly for material properties, biocompatibility, rate of biodegradation and used for the production of ideal stents. These will be characterized thoroughly leading to preclinical validation. All required production and manufacturing guidelines will be followed.

Consortium · 14 organisations

coordinator

LUCIDEON LIMITED

UK · €624,500

participant

THE UNIVERSITY OF WESTMINSTER LBG

UK · €578,972

participant

FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG

DE · €218,400

participant

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

UK · €208,315

participant

FUNDACION TEKNIKER

ES · €267,293

participant

SPINTEC ENGINEERING GMBH

DE · €100,073

participant

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV

DE · €470,035

participant

ASHLAND SPECIALTIES IRELAND LIMITED

IE · €317,990

participant

RUHR-UNIVERSITAET BOCHUM

DE · €325,586

participant

UNIVERSITY OF SOUTHAMPTON

UK · €358,863

participant

EURESCOM-EUROPEAN INSTITUTE FOR RESEARCH AND STRATEGIC STUDIES IN TELECOMMUNICATIONS GMBH

DE · €204,807

participant

POLITECNICO DI TORINO

IT · €241,946

participant

LIFE AND DEVICE SRL

IT · €296,025

participant

ARTERIUS LIMITED

UK · €366,326

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.